Liquidia Technologies Inc (LQDA) - Total Assets
Based on the latest financial reports, Liquidia Technologies Inc (LQDA) holds total assets worth $275.98 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Liquidia Technologies Inc for net asset value and shareholders' equity analysis.
Liquidia Technologies Inc - Total Assets Trend (2016–2024)
This chart illustrates how Liquidia Technologies Inc's total assets have evolved over time, based on quarterly financial data.
Liquidia Technologies Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Liquidia Technologies Inc's total assets of $275.98 Million consist of 80.4% current assets and 19.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 76.6% |
| Accounts Receivable | $2.72 Million | 1.2% |
| Inventory | $241.00K | 0.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $3.16 Million | 1.4% |
| Goodwill | $3.90 Million | 1.7% |
Asset Composition Trend (2016–2024)
This chart illustrates how Liquidia Technologies Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Liquidia Technologies Inc (LQDA) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Liquidia Technologies Inc's current assets represent 80.4% of total assets in 2024, an increase from 37.1% in 2016.
- Cash Position: Cash and equivalents constituted 76.6% of total assets in 2024, up from 17.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 1.7% of total assets.
Liquidia Technologies Inc Competitors by Total Assets
Key competitors of Liquidia Technologies Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Liquidia Technologies Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.20 | 6.33 | 5.63 |
| Quick Ratio | 1.96 | 6.33 | 5.63 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $123.78 Million | $180.37 Million | $54.33 Million |
Liquidia Technologies Inc - Advanced Valuation Insights
This section examines the relationship between Liquidia Technologies Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 169.79 |
| Latest Market Cap to Assets Ratio | 14.41 |
| Asset Growth Rate (YoY) | 94.6% |
| Total Assets | $230.31 Million |
| Market Capitalization | $3.32 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Liquidia Technologies Inc's assets at a significant premium (14.41x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Liquidia Technologies Inc's assets grew by 94.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Liquidia Technologies Inc (2016–2024)
The table below shows the annual total assets of Liquidia Technologies Inc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $230.31 Million | +94.63% |
| 2023-12-31 | $118.33 Million | -8.41% |
| 2022-12-31 | $129.20 Million | +37.84% |
| 2021-12-31 | $93.73 Million | -5.83% |
| 2020-12-31 | $99.53 Million | +44.58% |
| 2019-12-31 | $68.84 Million | +39.30% |
| 2018-12-31 | $49.42 Million | +232.93% |
| 2017-12-31 | $14.84 Million | +74.91% |
| 2016-12-31 | $8.49 Million | -- |
About Liquidia Technologies Inc
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The comp… Read more